Next Article in Journal
Reduction in Membranous Immunohistochemical Staining for the Intracellular Domain of Epithelial Cell Adhesion Molecule Correlates with Poor Patient Outcome in Primary Colorectal Adenocarcinoma
Previous Article in Journal
The Mammography Debate: The Senior Years
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 23
Issue 3
10.3747/co.23.3026
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Thyroid Hormone Autoantibodies: Are They a Better Marker to Detect Early Thyroid Damage in Patients with Hematologic Cancers Receiving Tyrosine Kinase Inhibitor or Immunoregulatory Drug Treatments?

by
P. Mondello
1,2,3,*,
M. Mian
4,
V. Pitini
1,
S. Cuzzocrea
2,
A. Sindoni
5,
M. Galletti
6,
M. Mandolfino
6,
D. Santoro
7,
S. Mondello
8,
C. Aloisi
7,
G. Altavilla
1 and
S. Benvenga
6
1
Department of Human Pathology, University of Messina, Messina, Italy
2
Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy
3
Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
4
Department of Hematology and CBMT, Hospital of Bolzano, Bolzano, Italy
5
Department of Biomedical Sciences and Morphological and Functional Images, University of Messina, Messina, Italy
6
Section of Endocrinology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
7
Department of Internal Medicine, University of Messina, Messina, Italy
8
Department of Neurosciences, University of Messina, Messina, Italy
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(3), 165-170; https://doi.org/10.3747/co.23.3026
Submission received: 2 March 2016 / Revised: 6 April 2016 / Accepted: 11 May 2016 / Published: 1 June 2016

Abstract

Background: Unlike cytotoxic agents, novel antineoplastic drugs can variably affect thyroid function and so impair patient outcomes. However, the widely used standard thyroid tests have demonstrated low sensitivity for detecting early thyroid damage that leads to dysfunction of the gland. To find a more reliable thyroid marker, we assessed the presence of antibodies binding thyroid hormones (thAbs) in a cancer population undergoing potentially thyrotoxic treatment. Methods: From April 2010 to September 2013, 82 patients with hematologic malignancies treated with tyrosine kinase inhibitors or immunoregulatory drugs were recruited. Healthy volunteers (n = 104) served as control subjects. Thyroid function, autoimmunity tests, thAbs, and thyroid sonography were assessed once during treatment. Results: Overall, thAb positivity was recorded in 13% of the entire cohort. In most cases, the thAbs were of a single type, with a predominance of T3 immunoglobulin G. More specifically, thAbs were detected in 11 cancer patients; and abnormal levels of thyroid-stimulating hormone, thyroglobulin antibody, and thyroperoxidase antibody were detected in 6 (p = 0.05), 0 (p = 0.0006), and 2 cancer patients (p = 0.001) respectively. Ultrasonographic alterations of the thyroid were observed in 12 cancer patients. In contrast, of the 104 healthy control subjects, only 1 was positive for thAbs (1%). Conclusions: We have demonstrated for the first time that thAbs are a reliable marker of early thyroid dysfunction when compared with the widely used standard thyroid tests. A confirmatory prospective trial aiming at evaluating thAbs at various time points during treatment could clarify the incidence and timing of antibody appearance.
Keywords: thAb; tyrosine kinase inhibitors; immunoregulatory drugs; hematologic malignancies thAb; tyrosine kinase inhibitors; immunoregulatory drugs; hematologic malignancies

Share and Cite

MDPI and ACS Style

Mondello, P.; Mian, M.; Pitini, V.; Cuzzocrea, S.; Sindoni, A.; Galletti, M.; Mandolfino, M.; Santoro, D.; Mondello, S.; Aloisi, C.; et al. Thyroid Hormone Autoantibodies: Are They a Better Marker to Detect Early Thyroid Damage in Patients with Hematologic Cancers Receiving Tyrosine Kinase Inhibitor or Immunoregulatory Drug Treatments? Curr. Oncol. 2016, 23, 165-170. https://doi.org/10.3747/co.23.3026

AMA Style

Mondello P, Mian M, Pitini V, Cuzzocrea S, Sindoni A, Galletti M, Mandolfino M, Santoro D, Mondello S, Aloisi C, et al. Thyroid Hormone Autoantibodies: Are They a Better Marker to Detect Early Thyroid Damage in Patients with Hematologic Cancers Receiving Tyrosine Kinase Inhibitor or Immunoregulatory Drug Treatments? Current Oncology. 2016; 23(3):165-170. https://doi.org/10.3747/co.23.3026

Chicago/Turabian Style

Mondello, P., M. Mian, V. Pitini, S. Cuzzocrea, A. Sindoni, M. Galletti, M. Mandolfino, D. Santoro, S. Mondello, C. Aloisi, and et al. 2016. "Thyroid Hormone Autoantibodies: Are They a Better Marker to Detect Early Thyroid Damage in Patients with Hematologic Cancers Receiving Tyrosine Kinase Inhibitor or Immunoregulatory Drug Treatments?" Current Oncology 23, no. 3: 165-170. https://doi.org/10.3747/co.23.3026

APA Style

Mondello, P., Mian, M., Pitini, V., Cuzzocrea, S., Sindoni, A., Galletti, M., Mandolfino, M., Santoro, D., Mondello, S., Aloisi, C., Altavilla, G., & Benvenga, S. (2016). Thyroid Hormone Autoantibodies: Are They a Better Marker to Detect Early Thyroid Damage in Patients with Hematologic Cancers Receiving Tyrosine Kinase Inhibitor or Immunoregulatory Drug Treatments? Current Oncology, 23(3), 165-170. https://doi.org/10.3747/co.23.3026

Article Metrics

Back to TopTop